SAPHO Syndrome Presenting as an Osteolytic Lesion of the Neck

Mateo, Lourdes; Sanint, Juana; Muguruza, Samantha Rodríguez; Morillo, Melania Martínez; Andrés, Ricard Pérez; Puigcerver, Sira Domenech

doi:10.1016/j.reumae.2015.11.022

Cited by 4 publications

(1 citation statement)

References 8 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…The skin lesions disappeared within several weeks following the fifth application of infliximab. Mateo et al 72 showed that treatment with infliximab improved clinical symptoms and radiological abnormalities and normalized ESR and CRP; however, plantar pustulosis persisted. Li et al 29 reported that seven (17.1%) of the 41 patients receiving anti-TNF therapies developed new skin lesions during treatment.…”

Section: Biologics In Sapho Syndromementioning

confidence: 99%

New Insights in the Treatment of SAPHO Syndrome and Medication Recommendations

Cheng¹,

Li²,

Tian³

et al. 2022

JIR

View full text Add to dashboard Cite

Synovitis, acne, pustulosis, hyperostosis, osteitis (SAPHO) syndrome is a rare autoinflammatory disease characterized by dermatological disorders and osteoarticular inflammatory lesions. This article reviews the application of biologics and other treatments based on the therapeutic target and the size of molecules in SAPHO syndrome. We found that drugs, especially biologics, have different effects on bone, joint, and skin damage. This may relate to the different inflammatory pathways involved in the osteoarticular and cutaneous symptoms in SAPHO patients. In this study, we provide stratified medication recommendations for SAPHO syndrome. Patients with osteoarticular symptoms can consider tumor necrosis factor blockers, JAK inhibitor, interleukin (IL)-1 inhibitor, and IL-17 inhibitor. Patients with cutaneous symptoms should consider IL-17 and JAK inhibitors. Apremilast, Tripterygium wilfordii Hook F, and bisphosphonates are other effective treatments.

show abstract

Section: Biologics In Sapho Syndromementioning

confidence: 99%

New Insights in the Treatment of SAPHO Syndrome and Medication Recommendations

Cheng¹,

Li²,

Tian³

et al. 2022

JIR

View full text Add to dashboard Cite

show abstract

SAPHO: has the time come for tailored therapy?

et al. 2019

View full text Add to dashboard Cite

SAPHO (synovitis, acne, pustulosis, hyperostosis and osteitis) syndrome is a heterogeneous condition combining osteoarticular and cutaneous manifestations. Conventional treatments are mostly ineffective. We hereby report two patients, the first with an aggressive form of disease and the second with an incomplete response to two different anti-TNF-α agents. Both were successfully treated with tocilizumab and ustekinumab, respectively, over a long period of time. A narrative review of a biological therapy in SAPHO syndrome yielded very little information on the specific use of these agents. We highlight the advantages of personalising therapy and describe emerging promising treatments for this disease.

show abstract